LQVTDSGLYRCVIYHPP TFA |
| Katalog-Nr.GC66386 |
LQVTDSGLYRCVIYHPP (LP17) TFA ist ein auslÖsender Rezeptor, der auf myeloischen Zellen (TREM-1) inhibitorisches Peptid exprimiert wird. LQVTDSGLYRCVIYHPP TFA lindert im Wesentlichen IschÄmie-induzierte Infarkte und neuronale Verletzungen. LQVTDSGLYRCVIYHPP TFA kann Zugang zum Gehirn erhalten und TREM-1 blockieren.
Products are for research use only. Not for human use. We do not sell to patients.
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
LQVTDSGLYRCVIYHPP (LP17) TFA is a triggering receptor expressed on myeloid cells (TREM-1) inhibitory peptide. LQVTDSGLYRCVIYHPP TFA substantially alleviates ischemia-induced infarction and neuronal injury. LQVTDSGLYRCVIYHPP TFA can get access into brain and block TREM-1[1].
LQVTDSGLYRCVIYHPP (LP17) (1 or 10 μM; 24 h) substantially decreases mRNA levels of pro-inflammatory cytokines and chemokines after reoxygenation and remarkably attenuates extracellular protein levels of IL-1β and IL-18 in a microglia oxygen-glucose deprivation (OGD) model[1].
LQVTDSGLYRCVIYHPP (LP17) (10 μM; 24 h) interacts with microglial SYK[1].
RT-PCR[1]
| Cell Line: | Primary microglia |
| Concentration: | 1 or 10 μM |
| Incubation Time: | 24 h |
| Result: | Decreased mRNA levels of NLRP3, IL-1β, IL-18, IL-6, CD16, CD32, iNOS, MCP-1, CXCL-1, and CXCL-2 after reoxygenation. |
Western Blot Analysis[1]
| Cell Line: | Primary microglia |
| Concentration: | 10 μM |
| Incubation Time: | 24 h |
| Result: | Suppressed ischemia/reperfusion-induced increments in CARD9, p-p65 in CARD9/NF-κB signaling and NLRP3, ASC, cleaved caspase-1, mature IL-1β, and mature IL-18 in NLRP3/caspase-1 signaling in a microglia oxygen-glucose deprivation (OGD) model. |
LQVTDSGLYRCVIYHPP (LP17) (0.5 or 1 mg/kg; intranasal; daily for 3 days) alleviates ischemia-induced infarction and neuronal injury in mice[1].
| Animal Model: | Adult male C57BL/6J mice (20-25 g), mice cerebral ischemia/reperfusion (I/R) model induced by middle cerebral artery occlusion (MCAO)[1] |
| Dosage: | 0.5 mg/kg or 1 mg/kg |
| Administration: | Intranasal administration, once daily for 3 consecutive days after MCAO |
| Result: | Abolished ischemia-induced TREM-1 elevation at 1 mg/kg. Significantly reduced infarct volume by 27.3%, induced a markedly reduction in TUNEL positive cells and FJC positive neurons at 1 mg/kg. Rescued neurological deficits and cognitive dysfunction of MCAO mice. Inhibited microglial M1 polarization and neutrophil infiltration. |
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *